Generalities

Mini-syMposiuM sponsors
30 Years of Clinical Pharmacy
a bright future ahead
DeaDlines
Abstract Submission extended Deadline
Early Registration Deadline
Financial Support Application Deadline
Registration Deadline for Abstract Presenters
Late Registration Deadline
20 July 2009
31 July 2009
20 September 2009
29 September 2009
23 October 2009
ESCP – GSASA Symposium on Clinical Pharmacy
Geneva, Switzerland 3 − 6 November 2009
Content
ESCP International Office
Voorstraat 13
NL-9285 NM Buitenpost
The Netherlands
Tel: +31 645 915 831
Fax: + 31 511543660
Email: info@escpweb.org
www.escpweb.org
Symposium Secretariat
ESCP-GSASA 2009
c/o MCI SUISSE SA
Rue de Lyon 75
CH-1211 Geneva 13, Switzerland
Tel: +41 22 33 99 588
Fax: +41 22 33 99 651
E-mail: escp-gsasa2009reg@mci-group.com
Symposium website
information, registration and accomodation
http://www.escp-gsasa2009.org
Symposium Committees
Symposium President
Johnny Beney, Switzerland
Organizing Committee
Susanna Kussmann-Gerber, Switzerland
Brigitte Waldispuehl, Switzerland
Johnny Beney, Switzerland
Erik Gerbrands, The Netherlands
Gert Laekeman, Belgium
Georges Zelger, Switzerland
Scientific Committee
Cecilia Bernsten, Sweden
Caroline Fonzo-Christe, Switzerland
Marcel Bouvy, The Netherlands
Kurt Hersberger, Switzerland
Markus Lampert, Switzerland
Vincent Launay-Vacher, France
Foppe van Mil, The Netherlands
Pierre Voirol, Switzerland – Chair
ESCP General Committee
Frank Jorgenson, Norway ESCP President
Cecilia Bernsten, Sweden Vice President
01
Gert Laekeman, Belgium Past President
Erik Gerbrands, The Netherlands Treasurer
Pat Murray, United Kingdom
Maria Skouroliakou, Greece
Marie-Caroline Husson, France
Piera Polidori, Italy
Johnny Beney, Switzerland
Martin Schulz, Germany
GSASA General Committee
Brigitte Waldispühl, Bellinzona President
Pascal Bonnabry, Genève Vice President
Georges Zelger, Yverdon Past President
Katharina Bracher, Lucerne
Treasurer
Cornelia Desax, Schlieren
Thomas Meister, Bern
Jean-Blaise Montandon, Neuchâtel
Edith Hufschmid Thurnherr, Thun
Joël Wermeille, Moutier
Peter Wiedemeier, Zürich
Pierre Voirol, Lausanne
Stefanie Deuster, Basel
Invitation from the Presidents ........................................................
2
Generalities ...................................................................................
Awards .............................................................................................
Contributions from participants .......................................................
Financial support for ESCP Conference Attendees .........................
Industry Sponsorship and Exhibition Opportunities ........................
Practical Informations ...................................................................
Registration and Accommodation ...................................................
3
4
5
6
7
8
10
Scientific Programme .................................................................
Tuesday, November 3, 2009 ...........................................................
Wednesday, November 4, 2009 ..... ...............................................
Thursday, November 5, 2009 .........................................................
Friday, November 6, 2009 ...............................................................
Workshop Summaries ...................................................................
13
13
15
21
25
29
Programme at a glance .......................................................... 18
wElComE by thE PrESIdEntS of ESCP, GSaSa & thE SymPoSIum
Dear Colleagues,
On behalf of the Swiss Society of Public Health Administration and Hospital Pharmacists –
GSASA and the European Society of Clinical Pharmacy – ESCP, we are pleased to invite you
to the 38th European Symposium on Clinical Pharmacy in Geneva.
In 2009, the European Society of Clinical Pharmacy celebrates its 30th anniversary. ESCP
was indeed founded in Lyon in 1979 by clinical practitioners, researchers and educators from
various countries across Europe. After 30 years of continuous development, the value of
clinical pharmacy is now recognized and we anticipate a bright future. Within an increasingly
complex environment, health care professionals must coordinate their actions and learn
how to use new technologies to maximize efficiency. Such challenges and pressure on
performance should not divert us from our essential purpose: Patient Care.
Come and join us in Geneva to discuss and learn on Patient Focused Care, Multidisciplinary
Cooperation and Integrating Technologies in our Work. During 3 days we will meet
international experts reporting on recent developments, exchange and share knowledge
during workshops, oral communications and poster sessions. Besides its extensive and
diverse programme addressing education, research and patient care, this symposium offers
you ample opportunities for networking and friendly socializing.
Gathering in the host city of the United Nations, the World Health Organization, and the
International Red Cross, this meeting will not only guarantee an exciting scientific programme
but also a relaxing stay in Geneva, the central crossroads of Western Europe.
Johnny beney
Symposium President
brigitte waldispuehl
GSASA President
frank Jørgensen
ESCP President
05
UNO Entrance, Geneva 2009
02
Generalities
Awards
4
Contributions from participants
5
Financial support for ESCP Conference Attendees
6
Industry Sponsorship and Exhibition Opportunities
7
Practical Informations
8
Registration and Accommodation
10
Generalities
04
Awards
ESCP Poster Award and Oral Communication Award 2009
The ESCP will present an award for the best poster and the best oral communication
presented during the Symposium. Everyone is invited to submit abstracts for consideration.
Criteria for Award Winners
The jury will review the submitted abstracts according to the selection criteria for award
winners. These criteria are applicable for both the ESCP Poster Award and Oral
Communication Award. They are:
1. Originality and aim: valid innovative work is valued over more routine methods; new
findings are valued over a confirmation of old findings, unless controversial. The aim of
the work should be clear.
2. Design of a study or service: the study or service should be described in sufficient detail
to allow understanding of its purpose and general structure; the objectives and methods
should be clearly defined.
3. Results: results or accomplishments should be stated concisely and should relate to the
original aim and objectives. Final results and accomplishments are rated more highly than
interim reports.
4. Conclusions: conclusions should address the aim and objectives and should follow
logically from the results; the utility of the data and their potential role in the
management of patients should be emphasised.
5. Value to clinical pharmacy: a subject is of practical significance if it stimulates discussion
among clinical pharmacists. The poster or oral communication can describe a novel
approach or technique in practice or develop the role of the clinical pharmacist in the
care of patients.
05
Submission
All participants of the symposium are invited to make submissions for adjudication by the
Scientific Committee of the symposium. The committee will accept or reject the work on the
basis of the structured abstract. All accepted submissions, except oral communications, will
be presented in poster format. Accepted submissions for the learning resource centre will be
presented as video or software presentation.
Acceptance or rejection will be sent to the authors on 14 September 2009.
After acceptance, authors are entitled to register at the early-bird-fee for another 14 days:
deadline 29 September 2009.
How to Submit an Abstract
Abstracts may only be submitted electronically via www.escp-gsasa2009.org  Abstracts
(ESCP – GSASA Symposium on Clinical Pharmacy). Carefully fill in the online form, providing
all requested information.
The deadline for submission has been extended to 20 July 2009, Midnight CET.
Abstracts submitted after the deadline will not be accepted.
Poster Presentation and Display
Posters related to different subjects within the scope of clinical pharmacy will be displayed
during the symposium from 4 to 6 November 2009. Accepted submissions will be presented
as a poster. Selected submissions considered to have especially broad appeal may be
assigned to a poster discussion forum or an oral communication. If an abstract has been
accepted for presentation as an oral communication, authors are not required to present
their work also as a poster.
Authors will be asked to be present at their poster during the coffee breaks. The maximum
size of the poster is 90 cm wide by 160 cm high. Adhesive material for poster presenters
is provided by the organisers.
Poster Discussion Forums
In poster discussion forums authors will give 8-minute presentations on the content of their
abstracts, including 3-minute discussions with questions and answers. The authors will also
present posters in the poster area.
Oral Communications
Oral communications consist of 15-minute presentations by the authors on the contents
of their abstracts, including 5-minute discussions with questions and answers. Authors are
not required to present their work also as a poster.
Generalities
Generalities
The deadline for submission of abstracts has been extended to 20 July 2009,
Midnight CET.
Abstracts submitted after the deadline will not be accepted.
Contribution from Participants
06
Financial Support for Conference Attendees
Andorra
Antigua and Barbuda
Aruba
Australia
Channel Islands
Cyprus
Czech Republic
Denmark
Guam
Hong Kong, China
Hungary
Iceland
Austria
Equatorial Guinea
Ireland
Bahamas, The
Bahrain
Estonia
Faeroe Islands
Isle of Man
Israel
Barbados
Finland
Italy
Belgium
Bermuda
Brunei Darussalam
Canada
Cayman Islands
France
French Polynesia
Germany
Greece
Greenland
Japan
Korea, Rep.
Kuwait
Liechtenstein
Luxembourg
Macao, China
Malta
Monaco
Netherlands
Netherlands
Antilles
New Caledonia
New Zealand
Northern Mariana
Islands
Norway
Oman
Portugal
Puerto Rico
Qatar
San Marino
Saudi Arabia
Singapore
Slovak Republic
Slovenia
Spain
Sweden
Switzerland
Trinidad and Tobago
United Arab Emirates
United Kingdom
United States
Virgin Islands (U.S.)
An additional condition is that the applicant must be active in developing clinical
pharmacy in his/her country. As this would be difficult to measure, ESCP requests that:
 The pharmacist has an abstract submitted and accepted for presentation at the symposium
 The pharmacist writes a short article on the symposium, which should be published in her/
his national journal. A copy of this publication should be sent to the ESCP International Office
 The pharmacist is interviewed during the symposium and the interview will be edited for
publication in the ESCP Newsletter.
In granting financial support, priority will be given to the following applicants:
 ESCP Members, taking into account the duration of their membership
 Applicants whose abstracts have been accepted for presentation as oral communication or
poster discussion forum during the symposium
 Applicants with the most experience in clinical pharmacy, which will be determined by the
quality of abstract(s) submitted and the applicants’ Curriculum Vitae
 Applicants who have not previously received financial support from ESCP
Should you wish to benefit from such support and are able to meet the criteria described
above, we invite you to send your financial support request and Curriculum Vitae by e-mail
to the ESCP International Office at info@escpweb.org
The deadline to submit financial support applications is 20 September 2009.
07
Demonstrate your commitment to the rational and appropriate use of medicines by
exhibiting or becoming a sponsor at the ESCP-GSASA Symposium on Clinical Pharmacy.
The sponsorship opportunities offer something for every budget and marketing strategy
to raise your company’s profile with a combination of advertising, sponsorship and other
promotional items. An exhibition will be organised in conjunction with the symposium. In
addition, a wide range of additional promotional items ranging from inserts in delegates bags,
to pens, adverts and more is also being offered.
The symposium also offers the opportunity for your company to be directly involved and
increase visibility and impact by organising a satellite symposium. Time slots for satellite
symposia are available at lunch time.
Contact for Exhibitors and Sponsors
To reserve your space and participation today or to know more about promotional
opportunities, please contact the GSASA sponsoring taskforce in Lausanne, Switzerland:
Susanna Kussmann, GSASA Sponsoring Taskforce
Tel: +41 21 784 01 44; Fax: +41 21 784 01 44; Email susanna.kussmann@gsasa.ch
For technical support of your already booked sponsoring item please contact:
Christopher Day, MCI Suisse SA, Rue de Lyon 75
1211 Geneva 13 – Switzerland
Tel: +41 22 33 99 650; Fax: + 41 22 33 99 621; Email: Christopher.Day@mci-group.com
We are grateful counting already by now the following companies among our
exhibitors/sponsors for the symposium 2009:
Abbott AG, Actavis Switzerland AG, Amgen Switzerland AG, AstraZeneca AG, B.Braun
Medical AG, Baxa Ltd, Baxter AG, Bayer Schering Pharma AG, Biotest Schweiz AG, BODE AG,
Boehringer Ingelheim (Schweiz) GmbH, Bristol-Myers Squibb SA, CSL Behring AG, Desitin
Pharma GmbH, Documed AG / E-Mediat AG, EBEWE Pharma Schweiz AG, Ecolab (Schweiz)
GmbH, ESSEX Chemie AG, Fresenius Kabi (Schweiz) AG, GE Healthcare Switzerland, Gebro
Pharma AG, GlaxoSmithKline AG, Grünenthal Pharma AG, GS1 Suisse - Medinorma Sàrl, Ibsa
Institut Biochimique AG, IDIS Ltd, Janssen-Cilag AG, Johnson & Johnson AG, Laboratorium
Dr. G. Bichsel AG, Eli Lilly (Suisse) S.A., MEDA Pharma GmbH, Mepha Pharma AG, Merck
Sharp & Dohme-Chibret AG, Mundipharma Medical Company, Nestle Healthcare Nutrition,
Novartis Consumer Health Schweiz AG, Novartis Pharma Schweiz AG, Nycomed Pharma AG,
Opopharma AG, OrPha Swiss GmbH, Pfizer AG, Proreo Pharma AG, Robapharm AG, Roche
Pharma (Schweiz) AG, RPS Publishing, Sandoz Pharmaceuticals AG, Sanofi-aventis (Suisse)
SA, Schülke & Mayr AG, Shire Human Genetic Therapies, Sintetica SA, Spirig Pharma AG,
Streuli Pharma AG, Systagenix, Teva Pharma AG, Vifor Pharma.
Generalities
Generalities
ESCP would like to assist in the education of clinical pharmacists in developing countries. A way
of doing this is to make the ESCP congresses more accessible for pharmacists from these
countries. ESCP therefore offers financial support, consisting of free registration to the 38th
ESCP European Symposium on Clinical Pharmacy. The pharmacist who requests financial assistance
should live and work in a developing country. Below you will find a listing of countries not
eligible, according to the World Bank list of economies April 2009.
Industry Sponsorship and Exhibition Opportunities
08
Practical Informations
MCI Suisse SA has been selected by ESCP-GSASA as the official Symposium Organiser for
the 2009 Symposium to process registrations, hotel reservations and abstract handling. All
correspondence should be sent to the Symposium Secretariat.
Symposium Venue
International Conference Centre Geneva (CICG)
17 rue de Varembé
CP 13
CH-1211 Geneva 20
Symposium Secretariat
ESCP-GSASA 2009
c/o MCI Suisse SA
75, rue de Lyon
CH-1211 Geneva 13
Phone: +41 22 33 99 588, Fax: +41 22 33 99 651
Email: escp-gsasa2009reg@mci-group.com
Official Conference Language
The official language of the conference will be English. No simultaneous translation will be
available.
Personal Invitation / Travel Documents
Participants are kindly invited to verify if they need a visa through the website of the
http://www.bfm.admin.ch/bfm/en/home/themen/einreise.html.
Participants requiring visa are strongly advised to make their application in their home country
at least one month before the intended date of travel.
An invitation letter can be requested during registration to the Symposium and will be
provided to duly registered participants. It is understood that such an invitation is intended to
help potential delegates raising funds. The letter of invitation is not a commitment on the part
of the Symposium to provide any financial support.
Information on A (H1N1) Flu
ESCP-GSASA is carefully monitoring the A (H1N1) flu situation. As of today, the World Health
Organization has not recommended international travel restrictions. At this time, we therefore
do not anticipate any changes to the meeting timing, location or programming. Updates will
of course be provided as needed.
(continued)
09
About Geneva
Get to know and view some pictures of the splendid city of Geneva through:
 City of Geneva http://www.ville-ge.ch
 Geneva Tourist Office http://www.geneve-tourisme.ch
Social Programme
As an addition to the scientific programme, a social programme has been developed to give
you the opportunity to explore the historical and natural beauties of Geneva, providing you
with the perfect environment for open debate and network.
Welcome Reception
An informal Welcome Reception will take place after the Opening Lecture by Richard Laing
(WHO) on Tuesday, 3 November 2009 at the Conference Centre (CICG).
Conference Dinner
Conference Dinner will take place on Thursday, 5 November 2009 at the Restaurant du Parc
des Bastions, a magic place inside a historical botanical garden. The restaurant is close to
the old town, the “Mur des Reformateurs” and the early buildings of the Geneva University,
founded in 1559 by Calvin.
The Café des Bastions is very centrally located, at walking distance to several hotels and
easily reachable by public transport.
Conference Dinner tickets can be booked and purchased through the Registration
System.
Note that the places are limited.
Excursions
Participants and accompanying persons may wish to take time out to enjoy Geneva’s
attractions by joining a variety of excursions. They are kindly invited to book their excursions
with KeyTours S.A.
KeyTours S.A.
7, rue des Alpes - BP 1745 - Genève 1
Tél. +41 22/731 41 40 - Fax. + 41 22/732 27 07
http://www.keytours.ch
Generalities
Generalities
Travel Insurance
It is recommended that participants obtain adequate cover for travel, health and accident
insurance before they depart from their countries. ESCP-GSASA and MCI as organizers cannot
accept responsibility for personal injuries, or loss of, or damage to, private property belonging
to the congress participants and accompanying persons.
Practical Informations
10
Symposium Registration and Hotel Accommodation
Symposium Registration
To register for the Symposium please complete the online form at
http://www.escp-gsasa2009.org Registration & Accommodation
Category
Early Fee ***
(until 31 July 09)
(continued)
11
Group Registrations
Groups with more than 10 participants will benefit from the Member fee. Please contact MCI
SUISSE SA escp-gsasa2009reg@mci-group.com for special conditions.
Normal Fee
(from 1 August
to 22 October 09
Late Fee
(as of 23 October 09
and on-site)
CHF 1’125,00 
Non-members
CHF 825,00

CHF 975,00

ESCP/GSASA Members*
CHF 675,00

CHF 825,00

CHF 975,00

Students **
CHF 415,00

CHF 450,00

CHF 490,00

Accompanying Persons
CHF 225,00

CHF 240,00

CHF 255,00

*
Please note that ESCP members who have not paid their membership fee for 2009 will not be
allowed the reduced registration fee.
** Student fee is available only to those under-graduate students who do not yet have their pharmacy degree. A letter of confirmation from the Head of Department or a copy of the student
card must be sent with the registration form.
*** Presenters of accepted abstracts will have the possibility to register at the early registration fee
until the 29 September 2009.
Indicative exchange rate as at 19.06.2009: 1 CHF = 0.66 Euro
Participant’s Registration Fee includes
 Admission to the scientific sessions from Tuesday, 3 November to Friday, 6 November 09
unless otherwise stated
 Congress documents, including badge and congress bag
 Final programme and abstract book
 Access to the commercial exhibition and posters
 Opening lecture and welcome reception on Tuesday, 3 November 2009 at the CICG
 Lunches and Coffee breaks
 Free city transportation pass for the duration of your stay if staying at a hotel in Geneva
 Tourist documentation on Geneva.
Accompanying Person’s Registration Fee includes
 Opening lecture and welcome reception on Tuesday, 3 November 2009 at the CICG
 Access to the commercial exhibition and posters
 Tourist documentation on Geneva
 Lunches and Coffee breaks
 Free city transportation pass for the duration of your stay if staying at a hotel in Geneva.
Continuing Education Credits
Pharmacists from Belgium, Croatia, Czech Republic, Finland, France, Germany, Italy, Portugal,
Switzerland, the Netherlands and the United Kingdom can obtain continuing education
credits for attending ESCP courses and symposia. For more information, please contact the
ESCP International Office or visit the ESCP stand during the symposium.
FPH-Points
Swiss pharmacist can claim 50 FPH-points per day or 150 FPH-points
for the whole congress for their participation at the congress
(Formation continue - Weiterbildung)
Confirmation
A letter of receipt will be sent to those who have completed the online registration form and
settled their payment. The confirmation letter should be presented at the registration desk in
order to receive the congress bag and badge.
Contact
ESCP-GSASA 2009
c/o MCI SUISSE SA
Rue de Lyon 75
CH-1211 Geneva 13, Switzerland
Tel: +41 22 33 99 588
Fax: +41 22 33 99 651
E-mail: escp-gsasa2009reg@mci-group.com
Registration Cancellation / Modification Terms and Conditions
Full payment is requested when registering (by credit card or by bank transfer). No
confirmation will be sent until MCI Suisse S.A. has received the payment.
All cancellations and changes to your original registration must be sent to MCI Suisse S.A.
in writing (letter, fax: +41 22 33 99 651, or e-mail to escp-gsasa2009reg@mci-group.com).
For cancellations received before 22 September 2009, fees will be refunded less
CHF 100.- for administrative costs. After this date, no refund will be possible.
A handling fee of CHF 50.- per registration will be charged for every registration modification
received after 6 October 2009.
Generalities
Generalities
Symposium Registration and Hotel Accommodation
SymPoSIum rEGIStratIon and hotEl aCCommodatIon
13
(continued)
hotel booking: General Information
As hotel accommodation is subject to availability, requests received after 8 September 2009
will not be guaranteed. Reservations are made on a first come, first served basis. Availability
of rooms in each category is limited.
Name of persons sharing rooms must be indicated. Rates are in Swiss Francs (CHF) and are
intended per room, per night, service and VAT included. For breakfast and city tax, please
refer to the list available in the online registration system.
Important: to guarantee your reservation, a deposit covering the first night of your stay is
required with your reservation (either by bank transfer or by credit card). Please indicate the
participant’s Name and “ESCP-GSASA 2009” on ALL payments.
From 22 September 2009, only payment made by credit card will be accepted.
Evening Opening Lecture
Tuesday, 3 November 2009, 18:30 – 19:30
Your booking will be confirmed upon receipt of your deposit payment. This prepaid deposit
will be deducted from your hotel bill when checking out from the hotel.
Special rules and regulations apply for group reservations. All group reservations will be
handled by MCI Suisse SA with separate contracts.
Pricing of drugs & transparency in health Care
Richard Laing, WHO
Broken Chair 1997, Daniel Berset, place des Nations
Generalities
Generalities
hotel Cancellation / modification terms and Conditions
All cancellations and changes to your original hotel booking must be sent to MCI Suisse SA
in writing (letter, fax : +41 22 33 99 651 or escp-gsasa2009reg@mci-group.com).
Please do not hesitate to contact the hotel directly.
For cancellations received before 22 September 2009, deposits will be refunded less CHF
100.- for administrative costs. After this date, no refund will be possible. In case of late
cancellations (from 22 September 2009), rooms cancelled, cancelled nights or no show, 1st
night stay will be retained and we reserve the right to charge the full stay if the hotel room
can not be re-sold.
tuesday, 3
12
Quai Wilson, Geneva 2009
Scientific Programme
Wednesday, 4 November 2009
wednesday, 4
The "Mur des Réformateurs" (1909), Geneva 2009
15
16
Scientific Programme of the day
Time
Morning Programme
09:30 – 10:00 Opening Ceremony
APPROACHES TO MultiDISCIPLINARY CARE
Time
14:00 – 16:00
Plenary Session 1A:
Interdisciplinary Cooperation
Chair: P. Voirol, Switzerland
10:00 – 10:30
L 1: Introduction to multidisciplinary care
J. Merrills, United Kingdom
10:30 – 11:00
L 2: Interdisciplinary perspectives on stroke treatment
A. Kinnear, United Kingdom, G. Mead, United Kingdom
14:30 – 15:00
11:00 – 11:30 Coffee Break– Poster viewing – Exhibition
15:30 – 16:00
10:00 – 12:30
11:30 – 12:00
12:00 – 12:30
L 3: Interdisciplinary perspectives on kidney transplant
M. Pascual, Switzerland, A. Carollo, Italy
Round Table Discussion I
17
14:00 – 14:30
15:00 – 15:30
Afternoon Programme | Parallel Sessions
Plenary Session 1B:
Multidisciplinary Cooperation in Drugs & Therapeutics Committes
Chair: Pascal Bonnabry, Switzerland
L 4: How the drug industry wants to become more ethical,
R. Bergström, Sweden
L 5: The Scottish Medicines Consortium (SMC) and how it works,
A. Timoney, United Kingdom
L 6: Dealing with prescribing ethics and conflicts of interest,
S. Hurst, Switzerland
Round Table Discussion II
14:00 – 16:00
Oral Communication I
Chair: Vincent Launay-Vacher, France
14:00 – 16:00
Workshops (summaries on page 29 - 34)
12:30 – 13:00 First Attendance Meeting
16:00 – 16:30 Coffee Break– Poster viewing – Exhibition
13:00 – 14:00 Lunch – Poster viewing – Exhibition
16:30 – 18:30
Plenary Session 1C:
Multidisciplinary Cooperation in Community Pharmacy
Chair: Olivier Bugnon, Switzerland
16:30 – 17:00
L 7: Quality circles in Switzerland, Olivier Bugnon, Switzerland
17:00 – 17:30
L 8: The family pharmacy in Portugal, S. Costa, Portugal
17:30 – 18:00
L 9: Pharmacotherapeutic consultation in the Netherlands,
R. Coolen van Brakel, The Netherlands
Round Table Discussion III
18:00 – 18:30
16:30 – 18:30
16:30 – 18:30
Poster Discussion Forum I
Chair: C. Bernsten, Sweden
Workshops (summaries on page 29 - 34)
Wednesday, 4
Wednesday, 4
APPROACHES TO MultiDISCIPLINARY CARE
Scientific Programme of the day
Programme at a Glance
18
Time
Wednesday, 4 November
Thursday, 5 November
Friday, 6 November
Approaches to multidisciplinary care
Patient oriented care
Technology and patient care
L 2: Interdisciplinary perspectives on stroke treatment,
A. Kinnear, UK, G. Mead, UK
Coffee Break
Plenary Session 2A : Talking to
patients about pharmacotherapyChair: M. Bouvy, NL
L 3: Interdisciplinary perspectives on kidney transplant
M. Pascual, CH, A. Carollo, IT
Pharmacotherapy Update I: New developments in anticoagulant therapy,
I. El Alamy, FR
Round Table Discussion I
Lunch –
Poster viewing – Exhibition
Opening Ceremony
L 1: Introduction to multidisciplinary care,
J. Merrills, UK
12:00
Plenary Session 1A: Interdisciplinary Cooperation
Chair: P. Voirol, CH
10:00
12:30
First Attendance Meeting
16:00
16:30
17:00
17:30
18:00
Opening
Lecture by
R. Laing
18:30
L 4: How the drug industry wants to become more ethical, R. Bergström, SE
L 5: The Scottish Medicines Consortium
(SMC) and how it works, A. Timoney, UK
L 6: Dealing with prescribing ethics and
conflicts of interest, S. Hurst, CH
Round Table Discussion II
Workshops
Oral Communication I :
Chair: V. Launay-Vacher, FR
15:30
L 7: Quality Circles in Switzerland,
O. Bugnon, CH
L 8: The family pharmacy in Portugal,
S. Costa, PT
L 9: Pharmacotherapeutic consultation in
the Netherlands, R. Coolen van Brakel, NL
Round Table Discussion III
L 14: Side effects of oral targeted
therapies – management strategies in
hospital and community settings, TBA
L 15: Drug-drug interactions and oral
targeted therapies, TBA
L 16: Compliance issues with oral
targeted therapies, TBA
& Round Table Discussion V
Coffee Break – Poster viewing – Exhibition
Coffee Break – Poster viewing – Exhibition
Workshops
Workshops
ESCP General Assembly
19:00
20:00
Parallel sessions
L 13: Oral targeted therapies: rationale
and overview of cellular mechanisms,
TBA
19:30
Welcome
Round Table Discussion VI :
Pharmacotherapy Update II : Similarity of biosimilars,
M. Pavlovic, FR
Sponsored
Sponsored
Lunch – Poster viewing – Exhibition
Mini-Symposium N°1 Mini-Symposium N°2
Parallel sessions
Poster Discussion Forum I:
Chair: C. Bernsten, NO
15:00
Plenary session 1B: Multidisciplinary cooperation in drugs & therapeutics committes,
Chair: P. Bonnabry, CH
14:30
Plenary session 1C: Multidisciplinary cooperation in
community pharmacy, Chair:
O. Bugnon, CH
GSASA
General
Assembly
Coffee Break – Poster viewing – Exhibition
Lunch – Poster viewing – Exhibition
Parallel sessions
14:00
Round Table Discussion IV
L 19: A national electronic patient dossier in the
Netherlands, F. van Mil, NL
 at 20:30 DINNER
Workshops
Workshops
Hot Topics Session
Chair: M. Daouphars, FR
13:00
L 12: Opioids for postpartal analgesia and the breastfed neonate – How clinical pharmacists communicate about pharmacogenomics, U. v. Mandach, CH
Coffee Break – Poster viewing – Exhibition
L 17: Implementing a drug information system with
CPOE in a hospital and its impact on patient care,
W. Haefeli, DE
L 18: E-prescription: beneficial for all stakeholders?
G. Bridell, SE
Poster Discussion Forum III:
Chair: TBA
11:30
L 11: Communicating with patients about medication adherence, S. Clifford, UK
Oral Communication III :
Chair: M. Lampert, CH
11:00
Plenary session 2B (ESCP–ESOP): Oral
targeted therapies: from the cell to
patient compliance, Chair:
M. Daouphars, FR, K. Meier, DE
10:30
Poster Discussion Forum II:
Chair: C. Fonzo-Christe, CH
09:30
Plenary Session 3 : : Integrating
technology in patient care
Chair: K. Hersberger, CH
L 10: Communicating risks to patients, D. Conen, CH
09:00
Oral Communication II :
Chair: F. van Mil, NL
Tues, 3 Nov
19
Closing Ceremony & Farewell drinks
SCIEntIfIC ProGrammE – PlEnary SESSIonS
wednesday, 4
aPProaChES to multIdISCIPlInary CarE
Plenary Session 1a:
Interdisciplinary Cooperation
Chair: P. Voirol, Switzerland
Plenary Session 1b:
multidisciplinary Cooperation in drugs
& therapeutics Committees
Chair: P. Bonnabry, Switzerland
Drugs and Therapeutics committee (DTC)
is a key place in hospitals as it define the
whole drug policy for the institution. Its
decisions have therefore important clinical
and economical consequences for the health
care givers, hospital administration and
pharmaceutical industries. The choices of
DTCs have to be rational and ethical. During
the session, we will discuss how DTC can
deal with ethics and conflicts of interest.
Efficient multidisciplinary collaborations have
been developed by community pharmacists
in different countries and in different
ways. They however all share the same
goal: increasing the quality (effectiveness,
safety and efficiency) of pharmacotherapy
in ambulatory care settings. During this
session, three models will be presented, one
in Switzerland, one in Portugal and one in
the Netherlands. The facilitators and barriers
encountered in the implementation of each
one will be discussed.
25
Scientific Programme
Thursday, 5 November 2009
thursday, 5
Clinical pharmacy means by definition a
close collaboration with other health care
givers. However, understanding what are
the expectations of each professional
category is crucial to implement a successful
activity. The goal of this session is to discuss
what works and what does not work in
the implementation of clinical pharmacy
services. After a general overview of the
topic, two examples, one on stroke and the
other one on kidney transplantation, will
be presented jointly by a physician and a
pharmacist.
Plenary Session 1C:
multidisciplinary Cooperation in
Community Pharmacy
Chair: O. Bugnon, Switzerland
The longest wooden banc of the world (1767), Geneva 2009
20
22
Scientific Programme of the day
Patient Oriented Care
Time
Patient Oriented Care
Morning Programme
Plenary Session 2A:
Patient Oriented Care
Chair: M. Bouvy, The Netherlands
Time
14:00 – 16:00
Afternoon Programme | Parallel Sessions
Plenary Session 2B: joint ESCP-ESOP Plenary Session
Oral Targeted Therapies: From the Cell to Patient Compliance
Chair: M. Daouphars, France, K. Meier, Germany
09:00 – 09:30
L 10: Communicating risks to patients,
D. Conen, Switzerland
14:00 – 14:20
09:30 – 10:00
L 11: Communicating with patients about medication adherence,
S. Clifford, United Kingdom
14:20 – 14:40
10:00 – 10:30
L 12: Opioids for postpartal analgesia and the breastfed neonate –
How clinical pharmacists communicate about pharmacogenomics,
U. v. Mandach, Switzerland
14:40 – 15:00
L 13: Oral targeted therapies: rationale and overview of cellular
mechanisms, TBA
L 14: Side effects of oral targeted therapies – management strategies
in hospital and community settings, TBA
L 15: Drug-drug interactions and oral targeted therapies, TBA
15:00 – 15:30
L 16: Compliance issues with oral targeted therapies, TBA
15:30 – 16:00
Round Table Discussion V
10:30 – 11:00 Coffee Break– Poster viewing – Exhibition
11:00 – 11:30
23
Round Table Discussion IV
11:30 – 12:00 Pharmacotherapy Update I: New developments in anticoagulant
therapy, I. El Alamy, France
12:00 – 14:00 Lunch – Poster viewing – Exhibition
12:00 – 14:00 Sponsored Mini-Symposium N°1 (Bayer)
12:00 – 14:00 Sponsored Mini-Symposium N°2 (Vifor)
16:00 – 16:30 Coffee Break– Poster viewing – Exhibition
14:00 – 16:00
Oral Communication II
Chair: F. van Mil, The Netherlands
14:00 – 16:00
Workshops (summaries on page 29 - 34)
16:30 – 18:30
Poster Discussion Forum II
Chair: C. Fonzo-Christe, CH
Workshops (summaries on page 29 - 34)
16:30 – 18:30
Thursday, 5
Thursday, 5
09:00 – 11:30
Scientific Programme of the day
24
SCIEntIfIC ProGrammE – PlEnary SESSIonS
25
PatIEnt orIEntEd CarE
Over the years the intrinsic safety of drugs
available on the market has increased
significantly. However at the moment we
have abundant number of drugs which,
although very effective when used properly,
have potential serious side effects. These
side effects especially occur when drugs are
not used properly in daily clinical practice. It
is therefore important to communicate with
patients on topics such as efficacy, safety
and adherence. Pharmacists have historically
been used to back-office task, but have
increasingly moved to the front office. In this
session we will we have several lectures on
communicating with patients on different
timely chosen topics.
Most of recently released oral anticancer
drugs inhibit tyrosine kinases of growth
factor receptors which pathways have been
demonstrated to be involved in disease
progression and/or dissemination. These
so-called ‘targeted therapies’ challenge
Scientific Programme
Friday, 6 November 2009
friday, 6
Plenary Session 2b:
joint ESCP-ESOP Plenary Session
oral targeted therapies:
from the Cell to Patient Compliance
Chairs: M. Daouphars, France
& K. Meier, Germany
oncology pharmacists’ knowledge and
practice for many reasons:
 understanding their mechanism of action
requires a good knowledge of cellular
pathways involved in carcinogenesis and
apoptosis,
 their side-effects, though usually not
life-threatening, have a high potential
to impair patient’s quality of life (e.g.
extensive skin reactions). Learning how
to manage these side-effects, both
in hospital and community settings,
is therefore paramount for oncology
pharmacists,
 patients may encounter adherence
difficulties, especially if facing side-effects
at home,
 metabolism mainly occur through CYP450
isoenzymes, leading to many potential
drug-drug interactions, particularly in
elderly patients.
Oncology pharmacists may play a crucial
role in patient education and information,
by managing side-effects, by improving
patients’ adherence to treatments, and by
performing medications reviews to identify
potential drug – drug interactions.
Vue of the Old Town of Geneva
thursday, 5
Plenary Session 2a:
Patient oriented Care
Chair: M. Bouvy, The Netherlands
26
Scientific Programme of the day
Technology and patient care
Time
Morning Programme
09:00 – 11:30
Plenary Session 3: Technology and Patient Care
Chair: K. Hersberger, Switzerland
09:00 – 09:30
L 17: Implementing a drug information system with CPOE in a hospital
and its impact on patient care, W. Haefeli, Germany
09:30 – 10:00
L 18: E-prescription: beneficial for all stakeholders?
G. Bridell, Sweden
10:00 – 10:30
L 19: A national electronic patient dossier in the Netherlands,
F. van Mil, The Netherlands
10:30 – 11:00 Coffee Break– Poster viewing – Exhibition
11:00 – 11:30
Round Table Discussion VI
11:30 – 12:00 Pharmacotherapy Update II: Similarity of biosimilars,
M. Pavlovic, France
Afternoon Programme | Parallel Sessions
14:00 – 16:00
Oral Communication III
Chair: M. Lampert, CH
14:00 – 16:00
Poster Discussion Forum III
Chair: TBA
14:00 – 16:00
Hot Topics Session
Chair: M. Daouphars, FR
14:00 – 16:00
Workshops (summaries on page 29 - 34)
16:00 – 17:00 Closing Ceremony & Farewell drinks
27
Technology and patient care
Plenary Session 3:
Technology and Patient Care
Chair: K. Hersberger, Switzerland
The use of technological innovations
and a systems approach can positively
influence the provision of medical and
pharmaceutical services. Electronic patient
records, computerized physician order entry
(CPOE) preferably linked to computerised
decision support (CDS) systems, automated
calculation of doses and dilutions, bar
coding, automated dispensing machines,
robotics and other automated processes
aim at higher precision and lower error
rates, thereby pharmacists can increase
their oversight of critical processes during
prescription preparation, dispensing and
patient care. For inpatient and ambulatory
settings the questions are: Does technology
improve patient safety and care? What is the
impact for clinical pharmacy practice?
This session will address different
applications of innovative technologies and
experiences from different countries.
Friday, 6
Friday, 6
12:00 – 14:00 Lunch – Poster viewing – Exhibition
Scientific Programme – Plenary sessions
Geneva "Mouette" & Quai Gustave-Ador (1856), Geneva
The Petrified (1979), sculpture by Carl Bucher, International RedCross Museum, Geneva
29
Workshop Summaries
30
Scientific programme – Workshops
WS 1: Drugs in Pregnancy and Lactation
Facilitator: Ursula von Mandach, Switzerland
During this workshop participants will
discuss drugs most frequently used related
to pregnancy associated complaints.
During this discussion problems around
these drugs will be looked at, and the role
of pharmacogenetics of drugs in breast
feeding. In smaller groups, the participants
will actively draw up and discuss a list of
potential harmful drugs for the baby.
WS 2: Measuring and Improving
Medication Compliance
Facilitators: Marie-Paul Schneider,
Switzerland, Marcel Bouvy, Netherlands,
Sarah Clifford, United Kingdom
WS 3: Learning together – Models
of Inter-professional Education
Facilitators: Moira Kinnear, United Kingdom,
Ann Snyder, USA, Dick Toering, Netherlands
Interprofessional education (IPE) has
WS 4: Indicators for Quality and Safety
of Pharmaceutical Care
Facilitators: Darren Ashcroft, United
Kingdom, Peter Noyce, United Kingdom,
Marcel Bouvy, Netherlands
Indicators are measurable elements of
care that give an indication of the quality
or safety of the care provided to patients.
Indicators can serve different purposes,
such as improving the transparency of care
and generating signals for providers of
care for areas that need improvement. The
workshop will give an overview of basic
concepts regarding the use and development
of indicators for quality and safety of care in
clinical pharmacy. Methodological issues in
indicator development, use and interpretation
will be discussed. Two indicator sets that
have been developed in the Netherlands and
the United Kingdom will be presented.
31
WS 5: Examining Safety Climate and
Culture in Pharmacy Settings
Facilitators: Darren Ashcroft, United Kingdom,
Peter Noyce, United Kingdom,
Marcel Bouvy, Netherlands
with a geriatric approach to discontinue
benzodiazepines and alcohol in this special
population.
This is a workshop of the ESCP-SIG Geriatrics.
International efforts to improve patient
safety have increasingly recommended that
healthcare organizations should consider
adopting safety management techniques
used in other high risk industries. This
workshop will provide participants with an
overview on the use of safety climate tools
in healthcare settings. Two safety culture/
climate tools designed specifically for use
in pharmacy settings will be presented.
Participants will also have the opportunity
to complete a self-assessment framework
to characterize the prevailing safety culture
within their own pharmacies.
WS 7: Evidence-Based Medicine:
How do we Apply Literature Data to a
Geriatric Population
Facilitators: Yolande Hanssens, Quatar/Belgium,
Louise Mallet, Canada
WS 6: Substance Abuse in the Elderly:
Is it a Problem?
Facilitators: Louise Mallet, Canada,
Bertrand Guignard, Switzerland
Misuse and abuse of legal and illegal
drugs is becoming an important problem
in the elderly. The overall prevalence of
drug abuse in older individual is difficult to
evaluate; up to 11% of older women misuse
and abuse prescription drugs. Usage of
benzodiazepines and alcohol is increasing
in our elderly population. It is also reported
that the “baby boomers” will be using illegal
drugs such as cocaine, LSD, heroin. The goal
of this workshop is to provide pharmacists
Published data, including randomized clinical
trials, mainly focus on patients up to the
age of 65. A limited number of trials include
elderly patients (65 and above). With an
aging population, it is important to ensure
that available information is correctly applied
to this aging population. With the help of
one or more examples, the participants well
learn how to evaluate a research article
systematically and critically
This is a workshop of the ESCP-SIGs
Medicine Information and Geriatrics.
WS 8: Pharmacoeconomics: The Good,
the Bad and the Ugly - A Practical
Approach to Assessing the Literature
Facilitators: Katherine Lyseng-Williamson,
New Zealand,
Keith Evans, United Kingdom
The cost, and cost effectiveness, of
pharmacological and other therapies play an
increasingly important part in the selection
of appropriate care by health care providers
and policy makers. Pharmacoeconomic
Workshops
Workshops
The workshop will give an overview of
methodology used to measure medication
compliance including patient self-report,
pharmacy dispensing data and electronic
measurements. Moreover possible causes
of non adherence will be discussed. The
participants will work on cases to calculate
compliance from medication record and
will learn how to discuss possible noncompliance with patients.
been defined as “occasions when two or
more professions learn with, from and
about each other to improve collaboration
and the quality of care” (CAIPE 2002).
IPE is developing in many European
countries (www.eipen.org) with and
without Pharmacy integration. The aim
of this workshop is to share examples
from established IPE programmes and
to encourage participants to consider
the actions they can take in their own
institutions to explore opportunities
for IPE. This is a workshop of the ESCP
Education & Training SIG and the
Education Committee.
Scientific programme – Workshops
32
Scientific programme – Workshops
Scientific programme – Workshops
(continued)
(continued)
studies attempt to assess cost and
clinical benefits of alternative healthcare
interventions to provide a decisionmaking framework; they should not be
about reducing costs, but should be about
maximising net benefits. The workshop
would define basic pharmacoeconomic
terms, the key factors necessary for a ‘good’
pharmacoeconomic analysis, and present a
simple scoring system based on this factors.
The scoring system would be used in the
small group setting to analyse two published
pharmacoeconomic analyses.
The clinical and practice-based education
has a major role in the pharmacy education.
Introducing clinical rotations (rounds) to
pharmacy education helps the pharmacist
for a better professional life in the future.
By increasing the exposure of pharmacist or
pharmacy students to patients and medical team
in their education, there will be an increased
understanding of patients, their diseases and
drug therapy and it will enhance communication
skills. The aim of this workshop is to discuss
the clinical practice based education in medical
teams for the clinical pharmacists and its
importance in the pharmacy education. It will
also help to clarify the roles of the different
participants in such clinical rotations.
In recent years, rising prices and growing
expenditures on oncology drugs have
caused significant concern among payers,
healthcare providers and patients. Across
Europe, health-care payers are confronted
by the challenges of scarce resource in the
face of almost infinite demands. Despite
budgetary constraints, there is tremendous
political pressure to have new drugs licensed
and made available to patients. Healthcare systems have had to become more
sophisticated to deal with this challenge.
Participants will discuss issues in relation
with these increasing costs and demands
in the field of (especially) oncology from a
European perspective. The formation of a
network will be stimulated.
This is a workshop of the ESCP-SIGs Cancer
Care and Pharmacoeconomics.
WS 11: Clinical Community Pharmacy
and Trial Development
Facilitators: Caroline Steensels, Belgium,
Gert Laekeman, Belgium
Based on the real world data and
experiences of a clinical trial imposed by
the Belgian Medicines Board (the Sinutab
trial), the participants will discuss the
difficulties of implementing a clinical trial
in community pharmacy practice. The
mentioned trial was eventually achieved
after five years. The unhappy events,
adverse opinions and structural objections
will be discussed. There is a purpose of
exchange coordinates at the end of the
workshop in order create a forum for
planning and conducting clinical trials
in community pharmacies and reporting
about the results during ESCP conferences.
WS 12: Successful Scientific Writing:
Original Research Papers
Facilitators: Foppe van Mil, Netherlands
and TBA
The results of scientific research are only
valuable for society, if they can be shared
with others in an understandable written
or oral format. Writing research papers
that can be accepted by a peer reviewed
journal, can be a challenging experience.
But there are a number of important
aspects that authors can pay attention to,
and that will facilitate acceptance. This
workshop will especially focus on scientific
articles in the format for Pharmacy World
& Science but most other scientific
journals have similar required formats.
After an introduction, the participants
will study and discuss examples of the
different stages of scientific papers in
smaller groups.
This is a workshop of the ESCP
Communication Committee.
WS 13: Successful Scientific Writing:
Getting Abstracts Accepted
Facilitators: Foppe van Mil, Netherlands and TBA
There are several possible formats for written
information such as abstracts or scientific
articles. Writing a good abstract is important
because it may lead to having an oral
presentation at a conference. There are also
many reasons why abstracts are not accepted
for a scientific conference. Apart from writing
a condensed text that represents the study
well, there are a number of other important
aspects that will facilitate acceptance. This
workshop will focus on abstracts, such as
expected by the ESCP. But it will also discuss
more general and ethical considerations about
submitting abstracts, such as authorships and
responsibilities.
This is a workshop of the ESCP Communication
Committee.
WS 14: The Role of Clinical Pharmacists
in Counselling and Preventing
Cardiovascular Disease
Facilitators: Daniela Scala, Italy
Piera Polidori, Italy
Alessio Provenzani, Italy
Barbara Andria, Italy
Cardiovascular Disease (CVD) is the major
cause of premature death in Europe. It is an
important cause of disability and contributes
to the escalating costs of health care. The
underlying atherosclerosis develops insidiously
over many years. Death from CVD often occurs
suddenly and before medical care is available.
Workshops
Workshops
WS 9: Inter-professional Training:
The Importance of Clinical Rounds
in Clinical Pharmacy Education
Facilitators: Fikret Vehbi Izzettin, Turkey,
Steve Hudson, United Kingdom,
Mesut Sancar, Turkey
WS 10: Access to Cancer Treatment in
Europe: Different Remedies for the
Shared Issues
Facilitators: Benoît Allenet, France,
Mikaël Daouphars, France
33
34
Scientific programme – Workshops
(continued)
WS 15: Research Techniques:
Interviews and Focus Groups for
Beginners
Facilitator: Mara P Guerreiro, Portugal
Workshops
In recent years there has been greater
acceptance and recognition of the value of
qualitative research, either alone or combined
with quantitative techniques. Yet, practicing
pharmacists undertaken small-scale research
and junior researchers face sometimes
difficulties in designing and conducting
studies using qualitative techniques; often
they get also disheartened by data analysis.
This workshop will focus on two techniques
commonly used in pharmacy research: focus
groups and interviews. Examples of the use
of these techniques will be discussed, as well
as advantages and limitations. The workshop
will also provide practical advice on sampling,
data collection and data analysis. This is a
workshop of the ESCP Research Committee.
WS 16: A Hands-on Approach to
Medication Review
Facilitators: Nina Griese, Germany,
Kurt Hersberger, Switzerland
The workshop is a mixture of a lecture and
hands-on exercises with medication profiles
and medication review. Different approaches to
medication review will be presented, together
with the circumstances under which they can
be useful. Three cases will be discussed. After
the workshop, participants should be able to
understand the different forms of medication
review, and under what circumstances they can
be useful in clinical practice.
This is a workshop of the Pharmaceutical
Care Network Europe.
WS 17: Pharmacokinetic /
Pharmacodynamic (Pk/Pd) Indices on
Antimicrobial Therapy. Impact and
Influence on Clinical Practice
Facilitator: Dolores Soy, Spain
Pharmacokinetic (PK) and pharmacodynamic
(PD) characteristics both influence dosing
regimens of antimicrobials. PK (the overall
disposition of the drug in the body) is
reflected by the serum concentration profile
over time. PD can be characterized by the
susceptibility of the pathogen to the drug,
determined by measuring the minimum
inhibitory concentration (MIC), which is a
potency of the drug. Participants will discuss
about increasing need to identify new
therapeutic approaches which improve the
chance to reduce the morbidity and obtain
successful outcomes, based on a relatively
new approach integrating PK and PD features
has been suggested to implement optimal
antibiotic dosing regimens.
This is a workshop of the ESCP-SIG
Pharmacokinetics.
Vue of St. Pierre Cathedral, Geneva 2009
The occurrence of CVD relates strongly to
lifestyle and to modifiable physiological and
biochemical factors. Risk factor modifications
have been shown to reduce CVD mortality and
morbidity. The purpose of this workshop is to
increase the awareness of pharmacist-patient‘s
relationship in order to make pharmacist’s
clinical intervention more effective and
efficient in the prevention of CVDs.
Impressum
Graphic design and layout: white suitcase, Geneva http://www.white-suitcase.ch
Printed on 100% recycled paper by: Médecine & Hygiène, Geneva, http://www.medhyg.ch
Photo Credits: Carola Dallmeier Zelger © 2009
Cover: Geneva, Panoramic vue with its legendary water fountain (jet d’eau)
page 14: Geneva, The Reformation Wall (Mur des Réformateurs,1909), International
Monument to the Reformation in the Parc des Bastions
page 28: Geneva, The Petrified (1979), by the Swiss sculptor Carl Bucher, International
Red Cross Museum
page 35: Geneva, Vue of St. Pierre Cathedral
page 36: Geneva, Alley in the Old Town of Geneva
Alley in the Old Town of Geneva, 2009
European Society of Clinical Pharmacy (ESCP)
The European Society of Clinical Pharmacy (ESCP) was founded in October 1979 during the
8th European Symposium on Clinical Pharmacy in Lyon, France. The objective of the Society
is to develop and promote the rational and appropriate use of drugs and medical devices
for the benefit of individuals and of society. Each year the Society organises an Annual
Symposium, usually held in October. At this Symposium, papers in the field of pharmacotherapy,
pharmacokinetics, clinical practice and various other subjects related to the aims of ESCP are
presented.
Swiss Society of Public Health Administration and Hospital Pharmacists (GSASA)
The Swiss Society of Public Health Administration and Hospital Pharmacists (GSASA) was
founded in 1948 in Zurich, Switzerland. It has developed into a professional association of
pharmacists, mostly active in public health administration and hospital pharmacy and has
become an increasingly important voice in the Swiss Healthcare System. GSASA is co-organiser
of the 38th European Symposium of Clinical Pharmacy taking place in Geneva.
Disclaimer
All the information on the scientific and social programme, as outlined in this Provisional
Programme, is subject to change in finalisation of the ESCP-GSASA European Symposium
Final Programme.